Pramoxiquest Oral Gel for Horses and Ponies

国家: 英国

语言: 英文

来源: VMD (Veterinary Medicines Directorate)

有效成分:

Moxidectin, Praziquantel

可用日期:

Zoetis UK Limited

ATC代码:

QP54AB52

INN（国际名称）:

Moxidectin, Praziquantel

药物剂型:

Oral gel

处方类型:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

治疗组:

Horses

治疗领域:

Endectocide

授权状态:

Expired

授权日期:

2012-07-18

产品特点

Revised: June 2014
AN: 01740/2013
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Pramoxiquest Oral Gel for Horses and Ponies
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 g contains:
ACTIVE SUBSTANCE:
Moxidectin
19.5 mg
Praziquantel
121.7 mg
EXCIPIENTS:
Benzyl alcohol
220.0 mg
Butylhydroxytoluene 0.8 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral gel
Pale yellow to orange/pink gel
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Horses and ponies.
4.2.
INDICATIONS FOR USE,SPECIFYING THE TARGET SPECIES
Indicated for the treatment of mixed cestodes and nematodes or
arthropods
infections, caused by moxidectin and praziquantel sensitive strains
of:
Large strongyles:

_Strongylus vulgaris_ (adult stages)

_Strongylus edentatus_ (adult stages)

_Triodontophorus brevicauda_ (adults)

_Triodontophorus serratus_ (adults)

_Triodontophorus tenuicollis _ (adults)
Small strongyles (adults and intraluminal larval stages):

_Cyathostomum _spp.

_Cylicocyclus _spp_._

_Cylicostephanus _spp_._

_Cylicodontophorus_ spp.

_Gyalocephalus _spp.
Ascarids:
Revised: June 2014
AN: 01740/2013
Page 2 of 6

_Parascaris equorum_ (adult)
Other species:

_Oxyuris equi _(adult stages)

_Habronema muscae _(adults)

_Gasterophilus intestinalis _(L2, L3)

_Gasterophilus nasalis _(L2, L3)

_Strongyloides westeri _(adults)

_Trichostrongylus axei_ (adults)
Tapeworm (adults):

_Anoplocephala perfoliata_

_Anoplocephala magna_

_Paranoplocephala mammillana_
The egg reappearance period of small strongyles is 90 days.
The veterinary medicinal product is effective against (developing)
intramucosal
L4 stages of small strongyles. At 8 weeks after treatment, early
(hypobiotic) EL3
stages of small strongyles are eliminated.
4.3.
CONTRAINDICATIONS
Do not administer to young foals less than 6.5 months.
Do not administer in cases of known hypersensitivity to the active
ingredients or
to any of the excipients.
The product has b